Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
14 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/fda-accepts-biologics-license-application-for-mucopolysaccharidosis-ii-treatment-302454515.html
21 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-302431734.html
28 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/27/3015292/0/en/AB2-Bio-signs-U-S-option-and-licensing-agreement-with-Nippon-Shinyaku-for-Tadekinig-alfa-for-an-ultra-rare-autoimmune-disease.html
15 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership-to-develop-and-commercialize-rgx-121-and-rgx-111-for-mps-diseases-302350270.html
02 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/02/3003570/0/en/Capricor-Therapeutics-Completes-Submission-of-Biologics-License-Application-to-the-U-S-FDA-for-Deramiocel-for-the-Treatment-of-Duchenne-Muscular-Dystrophy.html
13 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/13/2979922/0/en/Nippon-Shinyaku-and-Atsena-Therapeutics-enter-into-an-Exclusive-Strategic-Collaboration-for-ATSN-101-in-the-U-S-and-Japan.html
Excipients
ABOUT THIS PAGE
Nippon Shinyaku is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Fluoromethane Sulfoanilide Hydrochloride bulk offered by Nippon Shinyaku
Find a price of NS-065/NCNP-01 bulk offered by Nippon Shinyaku